Eli Lilly announced plans to invest $6 billion to build a manufacturing facility in Huntsville, Alabama to produce the oral GLP‑1 candidate orforglipron. The Huntsville site is the third of four U.S. manufacturing locations Lilly has signaled this year to support its obesity portfolio. The scale‑up underscores Lilly’s strategic pivot to vertically secure capacity for high‑demand metabolic medicines and to control supply chains for small‑molecule GLP‑1 manufacturing. The investment will influence regional biomanufacturing capacity, vendor selection and talent recruitment and may accelerate timing for commercial readiness if orforglipron advances to approval and widescale adoption.